Trial Details
COMPLETEDBasic Information
| Clinical ID | c852 |
|---|---|
| Identifier | NCT03524092 |
| Trial Title | A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Mirikizumab SC|DRUG: Mirikizumab IV|DRUG: Placebo SC |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Dothan |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2018-10-19 |
|---|---|
| Primary Completion Date | 2021-11-03 |
| Completion Date | 2024-12-13 |